Aberdeen Group plc Buys 54,713 Shares of Personalis, Inc. $PSNL

Key Points

• Aberdeen Group plc increased its stake in Personalis, Inc. by 3.2%, now holding approximately 1.99% of the company valued at $11,542,000 after acquiring 54,713 shares.
• Multiple large investors such as American Century Companies and Trexquant Investment LP have also significantly increased their holdings in Personalis, bringing institutional ownership to 61.91%.
• Analysts have mixed opinions on Personalis, with a consensus rating of Moderate Buy and an average price target of $7.42, despite recent reports indicating negative earnings and a challenging financial outlook.

Aberdeen Group plc grew its stake in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 3.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,759,497 shares of the company's stock after purchasing an additional 54,713 shares during the period. Aberdeen Group plc owned approximately 1.99% of Personalis worth $11,542,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. American Century Companies Inc. grew its stake in shares of Personalis by 33.9% in the 1st quarter. American Century Companies Inc. now owns 67,377 shares of the company's stock valued at $236,000 after purchasing an additional 17,056 shares during the period. Trexquant Investment LP grew its stake in shares of Personalis by 455.0% in the 1st quarter. Trexquant Investment LP now owns 122,959 shares of the company's stock valued at $432,000 after purchasing an additional 100,804 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Personalis by 55.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company's stock valued at $998,000 after purchasing an additional 101,706 shares during the period. XTX Topco Ltd grew its stake in shares of Personalis by 147.0% in the 1st quarter. XTX Topco Ltd now owns 82,666 shares of the company's stock valued at $290,000 after purchasing an additional 49,197 shares during the period. Finally, ARK Investment Management LLC grew its stake in shares of Personalis by 6.1% in the 1st quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company's stock valued at $25,231,000 after purchasing an additional 412,762 shares during the period. 61.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PSNL has been the topic of several recent analyst reports. Wall Street Zen raised Personalis from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of Personalis in a report on Wednesday, October 8th. HC Wainwright reissued a "buy" rating and issued a $8.50 target price on shares of Personalis in a report on Monday, September 8th. Finally, BTIG Research set a $6.00 target price on Personalis in a report on Wednesday, August 6th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $7.42.

Personalis Stock Performance

NASDAQ:PSNL opened at $8.53 on Thursday. The stock's fifty day moving average price is $5.83 and its two-hundred day moving average price is $5.35. Personalis, Inc. has a 52-week low of $2.83 and a 52-week high of $8.95. The company has a market cap of $756.44 million, a price-to-earnings ratio of -6.66 and a beta of 1.83.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts predict that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.